279 related articles for article (PubMed ID: 27530469)
1. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.
Talavera Pons S; Boyer A; Lamblin G; Chennell P; Châtenet FT; Nicolas C; Sautou V; Abergel A
Br J Clin Pharmacol; 2017 Feb; 83(2):269-293. PubMed ID: 27530469
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Shebley M; Liu J; Kavetskaia O; Sydor J; de Morais SM; Fischer V; Nijsen MJMA; Bow DAJ
Drug Metab Dispos; 2017 Jul; 45(7):755-764. PubMed ID: 28483778
[TBL] [Abstract][Full Text] [Related]
3. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment.
Hill L
Top Antivir Med; 2015; 23(2):92-6. PubMed ID: 26200709
[TBL] [Abstract][Full Text] [Related]
5. Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.
Gandhi Y; Eley T; Fura A; Li W; Bertz RJ; Garimella T
Clin Pharmacokinet; 2018 Aug; 57(8):911-928. PubMed ID: 29353349
[TBL] [Abstract][Full Text] [Related]
6. Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort.
Höner Zu Siederdissen C; Maasoumy B; Marra F; Deterding K; Port K; Manns MP; Cornberg M; Back D; Wedemeyer H
Clin Infect Dis; 2016 Mar; 62(5):561-7. PubMed ID: 26611779
[TBL] [Abstract][Full Text] [Related]
7. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.
Burgess S; Partovi N; Yoshida EM; Erb SR; Azalgara VM; Hussaini T
Ann Pharmacother; 2015 Jun; 49(6):674-87. PubMed ID: 25770114
[TBL] [Abstract][Full Text] [Related]
8. Drug interactions with new hepatitis C oral drugs.
Soriano V; Labarga P; Barreiro P; Fernandez-Montero JV; de Mendoza C; Esposito I; Benítez-Gutiérrez L; Peña JM
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):333-41. PubMed ID: 25553890
[TBL] [Abstract][Full Text] [Related]
9. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.
McConachie SM; Wilhelm SM; Kale-Pradhan PB
Expert Rev Clin Pharmacol; 2016; 9(2):287-302. PubMed ID: 26651915
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents.
Murray M
Clin Pharmacokinet; 2023 Oct; 62(10):1365-1392. PubMed ID: 37731164
[TBL] [Abstract][Full Text] [Related]
11. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
Garrison KL; German P; Mogalian E; Mathias A
Drug Metab Dispos; 2018 Aug; 46(8):1212-1225. PubMed ID: 29695614
[TBL] [Abstract][Full Text] [Related]
12. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection.
El-Sherif O; Khoo S; Solas C
Curr Opin HIV AIDS; 2015 Sep; 10(5):348-54. PubMed ID: 26248122
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.
Chu X; Chan GH; Houle R; Lin M; Yabut J; Fandozzi C
AAPS J; 2022 Mar; 24(3):45. PubMed ID: 35314909
[TBL] [Abstract][Full Text] [Related]
14. A Review of Daclatasvir Drug-Drug Interactions.
Garimella T; You X; Wang R; Huang SP; Kandoussi H; Bifano M; Bertz R; Eley T
Adv Ther; 2016 Nov; 33(11):1867-1884. PubMed ID: 27664109
[TBL] [Abstract][Full Text] [Related]
15. Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage?
Talavera Pons S; Lamblin G; Boyer A; Sautou V; Abergel A
Eur J Clin Pharmacol; 2014 Jul; 70(7):775-89. PubMed ID: 24817413
[TBL] [Abstract][Full Text] [Related]
16. The importance of drug-drug interactions in the DAA era.
Back D; Else L
Dig Liver Dis; 2013 Sep; 45 Suppl 5():S343-8. PubMed ID: 24091114
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach.
Snoeys J; Beumont M; Monshouwer M; Ouwerkerk-Mahadevan S
Clin Pharmacol Ther; 2016 Feb; 99(2):224-34. PubMed ID: 26259716
[TBL] [Abstract][Full Text] [Related]
18. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.
Macías J; Monge P; Mancebo M; Merchante N; Neukam K; Real LM; Pineda JA
HIV Med; 2017 Aug; 18(7):445-451. PubMed ID: 27882706
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibition features of direct-acting anti-hepatitis C virus agents against human organic anion transporting polypeptide 2B1.
Furihata T; Fu Z; Suzuki Y; Matsumoto S; Morio H; Tsubota A; Matsumoto S; Chiba K
Int J Antimicrob Agents; 2015 Oct; 46(4):381-8. PubMed ID: 26163159
[TBL] [Abstract][Full Text] [Related]
20. Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review.
Bellesini M; Bianchin M; Corradi C; Donadini MP; Raschi E; Squizzato A
Clin Drug Investig; 2020 Nov; 40(11):1001-1008. PubMed ID: 32809123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
